These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 29604902)
1. Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity. Kokonozaki M; Kanellou P; Pappa CA; Vyzoukaki R; Sarantoulaki S; Stavroulaki E; Kyriakaki S; Alegakis A; Boula A; Alexandrakis MG Crit Rev Oncog; 2017; 22(3-4):255-262. PubMed ID: 29604902 [TBL] [Abstract][Full Text] [Related]
2. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610 [TBL] [Abstract][Full Text] [Related]
3. Potential role of FLT3-ligand in the angiogenic process of multiple myeloma. Kokonozaki M; Tsirakis G; Devetzoglou M; Kyriakaki S; Antonakis A; Vyzoukaki R; Pappa CA; Tzardi M; Alexandrakis MG Leuk Res; 2015 Dec; 39(12):1467-72. PubMed ID: 26521986 [TBL] [Abstract][Full Text] [Related]
4. Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma. Alexandrakis MG; Pappa CA; Kolovou A; Kyriakaki S; Vyzoukaki R; Devetzoglou M; Tsirakis G Med Oncol; 2014 May; 31(5):953. PubMed ID: 24729186 [TBL] [Abstract][Full Text] [Related]
5. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma. Alexandrakis MG; Roussou P; Pappa CA; Messaritakis I; Xekalou A; Goulidaki N; Boula A; Tsirakis G Biomed Res Int; 2013; 2013():389579. PubMed ID: 23936794 [TBL] [Abstract][Full Text] [Related]
13. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Jurisić V; Colović M Med Oncol; 2002; 19(3):133-9. PubMed ID: 12482123 [TBL] [Abstract][Full Text] [Related]
14. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959 [TBL] [Abstract][Full Text] [Related]
15. Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients. Tsirakis G; Pappa CA; Kaparou M; Katsomitrou V; Hatzivasili A; Alegakis T; Xekalou A; Stathopoulos EN; Alexandrakis MG Eur J Histochem; 2011; 55(3):e21. PubMed ID: 22073368 [TBL] [Abstract][Full Text] [Related]